Affiliations 

  • 1 Vaccine Medical and Scientific Affairs, Pfizer, Rua Alexandre Dumas, 1860, São Paulo, 04717904, Brazil. [email protected]
  • 2 Vaccines Medical Affairs, Pfizer, São Paulo, Brazil
  • 3 Vaccines Medical Affairs, Pfizer, Buenos Aires, Argentina
  • 4 Vaccines Medical Affairs, Pfizer, Singapore, Singapore
  • 5 Vaccine Medical Affairs, Pfizer, Beirut, Lebanon
  • 6 Vaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc, Collegeville, PA, USA
  • 7 Vaccines Medical Affairs Emerging Markets, Pfizer, San Jose, Costa Rica
  • 8 Orbital Therapeutics, Cambridge, MA, 02139, USA
  • 9 Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil
Infect Dis Ther, 2023 May;12(5):1237-1264.
PMID: 37097556 DOI: 10.1007/s40121-023-00804-2

Abstract

The rapid rollout of vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic over the past 2 years has resulted in the use of various vaccine platforms and regional differences in COVID-19 vaccine implementation strategies. The aim of this narrative review was to summarize evolving COVID-19 vaccine recommendations in countries in Latin America, Asia, and Africa and the Middle East across various vaccine platforms, age groups, and specific subpopulations. Nuances in primary and booster vaccination schedules were evaluated, and the preliminary impact of such diverse vaccination strategies are discussed, including key vaccine effectiveness data in the era of Omicron-lineage variants. Primary vaccination rates for included Latin American countries were 71-94% for adults and between 41% and 98% for adolescents and children; rates for first booster in adults were 36-85%. Primary vaccination rates for adults in the included Asian countries ranged from 64% in the Philippines to 98% in Malaysia, with corresponding booster rates varying from 9% in India to 78% in Singapore; for adolescents and children, primary vaccination rates ranged from 29% in the Philippines to 93% in Malaysia. Across included African and Middle Eastern countries, primary vaccination rates in adults varied widely from 32% in South Africa to 99% in the United Arab Emirates; booster rates ranged from 5% in South Africa to 60% in Bahrain. Evidence from the regions studied indicates preference of using an mRNA vaccine as a booster on the basis of safety and effectiveness of observed real-world data, especially during circulation of Omicron lineages. Vaccination against COVID-19 remains of paramount importance to reduce the burden of disease; strategies to overcome vaccine inequity, fatigue, hesitancy, and misinformation and to ensure adequate access and supply are also important.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.